Who is sponsoring NCT04874818?

NCT04874818 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT04874818?

Interventions in NCT04874818: [89Zr]Df-IAB22M2C PET/CT scan.

What condition does NCT04874818 study?

NCT04874818 studies Lymphopenia Due to COVID-19, T-cell, PET Imaging.

Is NCT04874818 still recruiting?

NCT04874818 is currently terminated. Last updated 2 April 2025.

Last reviewed 2025-04-02 · How we verify

NCT04874818: Tangelo

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CD8+ T-cell PET/CT Imaging in COVID-19 Patients

Terminated Last updated 2 April 2025

What this trial tests

trial testing [89Zr]Df-IAB22M2C PET/CT scan in Lymphopenia Due to COVID-19 in 5 participants. Terminated before completion.

Timeline

14 February 2022

Primary endpoint
31 December 2022

31 December 2022

Quick facts

Lead sponsor	Radboud University Medical Center
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	5
Start date	14 February 2022
Primary completion	31 December 2022
Estimated completion	31 December 2022
Sites	1 location across Netherlands

Drugs / interventions tested

[89Zr]Df-IAB22M2C PET/CT scan

Conditions studied

Lymphopenia Due to COVID-19 — all drugs for Lymphopenia Due to COVID-19 →
T-cell — all drugs for T-cell →
PET Imaging — all drugs for PET Imaging →

Sponsor

Radboud University Medical Center

Who can join

50 and older, any sex, with Lymphopenia Due to COVID-19 or T-cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A subset of patients diagnosed with severe acute respiratory syndrome (SARS)-CoV2 infection present with lymphopenia. The degree of lymphopenia, and in particular reduced cluster of differentiation (CD)8+ T-cell numbers, is correlated with clinical deterioration and intensive care unit (ICU) admission. The underlying reasons for lymphopenia in coronavirus disease (COVID)-19 is currently unclear, We aim to assess differences in the in vivo distribution of CD8+ T-cells in patients with proven SARS-CoV2 presenting with lymphopenia or with normal lymphocyte counts, using Zirconium-89 (\[89Zr\])Df-IAB22M2C positron emission tomography (PET) imaging.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients.
Caldrer S, Mazzi C, Bernardi M, Prato M, et al · · 2021 · cited 30× · PMID 34925369 · DOI 10.3389/fimmu.2021.789735
Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.
van der Geest KSM, Sandovici M, Nienhuis PH, Slart RHJA, et al · · 2022 · cited 21× · PMID 35733858 · DOI 10.3389/fmed.2022.902155
Preliminary evidence of localizing CD8+ T-cell responses in COVID-19 patients with PET imaging.
Koenen HJPM, Kouijzer IJE, de Groot M, Peters S, et al · · 2024 · cited 1× · PMID 38813383 · DOI 10.3389/fmed.2024.1414415

Verify or expand the search:

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04874818 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 2 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04874818.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing